Global Cardiovascular Therapeutic Drugs Market Trends and Key Busines April.2017 | Page 2

Global Cardiovascular Therapeutic Drugs Market According to the report "Cardiovascular Therapeutic Drugs Market", published by Market Data Forecast, the global market is projected to reach USD 141.38 Billion by 2021, at a CAGR of 2.2% from 2016 to 2021. Cardiovascular therapeutic drugs are the prescribed drugs and medicines for the diseases that are related to the structure and function of the heart and blood vessels. The past few decades have witnessed significant success in the development of highly effective drug therapies for common cardiovascular disease. The widespread use of these therapies along with the rising cardiovascular disease accounts for the increasing market for cardiovascular therapeutics. While cardiovascular disorders remains the major cause of morbidity and mortality in the world, the therapeutic drugs market is driven by the increasing aging population, epidemic of general medical problems like obesity & diabetes and growth in the per capita medical spending. However, shrinking target population, rising cost of drug development are the major restraint faced by the market. And, despite the wide prevalence of the cardiovascular diseases, pipelines for drug development products have been stagnant for variety of reasons. Global Cardiovascular therapeutic drugs market is segmented by type of disease, drug class and region. 1. By Disease:        Arteriosclerosis Cardiac arrhythmias Myocardial infarction acute coronary syndrome Peripheral artery disease Coronary artery disease Other Cardiovascular diseases 2. By Drug Class:   Monotherapies combination drug classes 3. By Geography      North America Europe Asia-Pacific Latin America Middle-East & Africa Some of the major companies leading in the industry includes Bayer, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Novartis, Merck, Takeda, Sanofi, Pfizer and boehringer ingelheim. [phone] | www.marketdataforecast.com | [email protected]